MCID: PRP021
MIFTS: 49

Peripheral Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Neoplasm

MalaCards integrated aliases for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 12 15
Peripheral Nervous System Neoplasms 44 73
Nerve Sheath Neoplasm 12 76
Nerve Sheath Tumors 12 73
Neoplasm of Peripheral Nerve 12
Nerve Sheath Neoplasms 44
Tumor of Pns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1192
NCIt 50 C3321 C4972

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology : 12 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary : Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to epithelioid malignant peripheral nerve sheath tumor and ganglioneuroma, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Akt Signaling and PI3K-Akt signaling pathway. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A nerve sheath tumor is a type of tumor of the nervous system (nervous system neoplasm) which is made up... more...

Related Diseases for Peripheral Nervous System Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
# Related Disease Score Top Affiliating Genes
1 epithelioid malignant peripheral nerve sheath tumor 33.9 ENO2 NF1
2 ganglioneuroma 30.8 ENO2 MYCN NTRK1 NTRK2
3 autonomic nervous system neoplasm 30.8 AKT1 ALK BACE1 CASP3 CD177 CNTN6
4 cellular schwannoma 30.6 CD34 NF1 TP53
5 adenocarcinoma 30.4 AKT1 ALK MYC TP53
6 ewing sarcoma 30.3 AKT1 ALK CASP3 CD34 ENO2 MFRP
7 pheochromocytoma 30.2 CASP3 ENO2 NF1 NGF NTRK1 TH
8 meningioma, familial 30.0 AKT1 CD34 ENO2 NF1 TP53
9 gastrointestinal stromal tumor 30.0 AKT1 CD34 ENO2 NF1 TP53
10 neuroblastoma 29.7 AKT1 ALK BACE1 CASP3 ENO2 MYC
11 malignant peripheral nerve sheath tumor with perineurial differentiation 12.4
12 malignant melanocytic peripheral nerve sheath tumor of mediastinum 12.3
13 malignant cardiac peripheral nerve sheath neoplasm 12.3
14 neurofibrosarcoma 12.2
15 neurofibroma 12.1
16 malignant glandular tumor of peripheral nerve sheath 11.6
17 malignant melanocytic neoplasm of the peripheral nerve sheath 11.5
18 neurilemmoma 11.5
19 malignant triton tumor 11.3
20 melanocytic psammomatous mpnst 11.3
21 chromosome 17q11.2 deletion syndrome, 1.4-mb 11.1
22 chromosome 17q11.2 deletion syndrome 11.1
23 painful orbital and systemic neurofibromas-marfanoid habitus syndrome 11.1
24 sarcoma 10.5
25 melanoma 10.4
26 gliofibroma 10.3 NF1 TP53
27 parameningeal embryonal rhabdomyosarcoma 10.3 ALK TP53
28 central nervous system benign neoplasm 10.3 ENO2 MYCN TP53
29 prolactin producing pituitary tumor 10.3 NGF NTRK1 TP53
30 cerebral neuroblastoma 10.3 ENO2 NGF TP53
31 optic nerve neoplasm 10.3 ENO2 NF1 TP53
32 juvenile pilocytic astrocytoma 10.3 ENO2 NF1 TP53
33 adult medulloblastoma 10.3 ENO2 MYCN TP53
34 meningeal melanomatosis 10.3 ENO2 NGF TP53
35 bone ewing's sarcoma 10.3 ENO2 MYC MYCN
36 optic nerve glioma 10.3 ENO2 NF1 TP53
37 olfactory neuroblastoma 10.3 ENO2 NTRK1 NTRK2
38 sarcoma, synovial 10.3
39 cauda equina neoplasm 10.3
40 autonomic nervous system benign neoplasm 10.3 ENO2 MYCN NF1 NTRK1
41 causalgia 10.3 ENO2 NGF NTRK1
42 cellular neurofibroma 10.3 CD34 TP53
43 plexiform schwannoma 10.3 CD34 ENO2 NF1
44 ovary sarcoma 10.3 CD34 MYC
45 lung meningioma 10.3 CD34 ENO2
46 childhood medulloblastoma 10.3 MYC MYCN TP53
47 intravascular fasciitis 10.3 ALK CD34
48 adrenal neuroblastoma 10.3 ENO2 MYCN
49 ovarian angiosarcoma 10.3 CD34 MYC
50 rare adenocarcinoma of the breast 10.3 AKT1 TP53

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

GenomeRNAi Phenotypes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.6 AKT1 ALK MYC NF1 NTRK2
2 Decreased viability GR00221-A-2 9.6 AKT1 NF1 NTRK2
3 Decreased viability GR00221-A-3 9.6 AKT1 MYC
4 Decreased viability GR00221-A-4 9.6 AKT1 ALK NF1 NTRK2
5 Decreased viability GR00402-S-2 9.6 AKT1 ALK MYC NF1 NTRK2

MGI Mouse Phenotypes related to Peripheral Nervous System Neoplasm:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 AKT1 ALK BACE1 CASP3 CNTN6 ENO2
2 growth/size/body region MP:0005378 10.41 AKT1 ALK BACE1 CASP3 ENO2 MYC
3 cellular MP:0005384 10.36 AKT1 BACE1 CASP3 CD34 ENO2 MYC
4 homeostasis/metabolism MP:0005376 10.32 AKT1 ALK BACE1 CASP3 CD34 MYC
5 mortality/aging MP:0010768 10.3 AKT1 ALK BACE1 CASP3 MYC MYCN
6 nervous system MP:0003631 10.3 AKT1 ALK BACE1 CASP3 CNTN6 ENO2
7 integument MP:0010771 10.24 AKT1 ALK BACE1 CASP3 CD34 MYC
8 muscle MP:0005369 10.09 AKT1 BACE1 CASP3 MYC MYCN NF1
9 hearing/vestibular/ear MP:0005377 10.07 CASP3 MYC NF1 NTRK1 NTRK2 NUMBL
10 normal MP:0002873 10.03 AKT1 BACE1 MYC MYCN NF1 NGF
11 liver/biliary system MP:0005370 10.02 AKT1 MYC MYCN NF1 NTRK2 TH
12 neoplasm MP:0002006 9.95 AKT1 ALK CD34 MYC NF1 TH
13 no phenotypic analysis MP:0003012 9.92 BACE1 CASP3 MYC MYCN NGF NTRK1
14 pigmentation MP:0001186 9.7 ALK CASP3 MFRP MYC NF1 NTRK1
15 respiratory system MP:0005388 9.65 AKT1 ALK CASP3 ENO2 MYCN NF1
16 vision/eye MP:0005391 9.36 ALK CASP3 MFRP MYCN NF1 NGF

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6 Gentamicins Phase 4,Not Applicable
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
10 Analgesics Phase 4,Phase 2,Phase 1
11 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
12 Central Nervous System Stimulants Phase 4,Not Applicable
13 Neurotransmitter Uptake Inhibitors Phase 4
14 Dopamine Uptake Inhibitors Phase 4
15 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Dopamine Agents Phase 4,Not Applicable
17 Central Nervous System Depressants Phase 4,Phase 1
18 Anesthetics Phase 4,Not Applicable
19 Anesthetics, Intravenous Phase 4
20 Adrenergic Agents Phase 4
21 Hypnotics and Sedatives Phase 4
22
Glycopyrrolate Phase 4 596-51-0 3494
23 Adrenergic alpha-2 Receptor Agonists Phase 4
24 Adrenergic alpha-Agonists Phase 4
25 Adrenergic Agonists Phase 4
26 Anesthetics, General Phase 4
27
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
28
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
29
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
30
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
31
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
32
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
33
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
34
Chlorhexidine Approved, Vet_approved Phase 2, Phase 3 55-56-1 2713 9552079
35
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 6055-19-2, 50-18-0 2907
36
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
37 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
38 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
40
Isophosphamide mustard Phase 3,Phase 2 0
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Anticonvulsants Phase 2, Phase 3,Phase 1
43 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
44 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
45 Excitatory Amino Acids Phase 2, Phase 3
46 Calcium, Dietary Phase 2, Phase 3
47 Diuretics, Potassium Sparing Phase 2, Phase 3
48 Chlorhexidine gluconate Phase 2, Phase 3
49 Excitatory Amino Acid Antagonists Phase 2, Phase 3
50 Sodium Channel Blockers Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 247)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
3 Dexmedetomidine and Propofol for Pediatric MRI Sedation Recruiting NCT03513757 Phase 4 propofol;Dexmedetomidine
4 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
5 First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Unknown status NCT00921037 Phase 2, Phase 3
6 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
7 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Recruiting NCT02471339 Phase 3
9 Effect of Lamotrigine on Cognition in NF1 Recruiting NCT02256124 Phase 2, Phase 3 Lamotrigine;Placebo
10 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
13 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
14 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Unknown status NCT01661283 Phase 2 everolimus;bevacizumab
15 Medical Treatment of "High-Risk" Neurofibromas Unknown status NCT00846430 Phase 2 Peg-Interferon alpha-2b;Celecoxib (Celebrex);Temozolomide (temodar);Vincristine Sulfate (Oncovin)
16 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Completed NCT03090971 Phase 2 Diclofenac Sodium;Saline Solution
17 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
18 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Completed NCT02332902 Phase 2 Everolimus
19 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
20 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Completed NCT02096471 Phase 2 PD-0325901
21 Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Completed NCT01673009 Phase 2 Gleevec
22 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
23 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
24 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
25 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
26 Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Completed NCT01412892 Phase 2 RAD001: Everolimus
27 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
28 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
29 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Completed NCT01140360 Phase 1, Phase 2 Gleevec
30 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
31 Study of PEG-Intron for Plexiform Neurofibromas Completed NCT00396019 Phase 2 PEG-Intron
32 A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Completed NCT00853580 Phase 2 Lovastatin ™
33 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
34 Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Completed NCT00754780 Phase 2 Pirfenidone
35 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
36 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Completed NCT00634270 Phase 2 Sirolimus
37 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
38 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
39 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
40 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
41 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
42 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
43 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
44 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Completed NCT00076102 Phase 2 Pirfenidone
45 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
46 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
47 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Completed NCT00030264 Phase 2 Methotrexate;Vinblastine
48 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
49 R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Completed NCT00021541 Phase 2 tipifarnib
50 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

MalaCards organs/tissues related to Peripheral Nervous System Neoplasm:

41
Lung, Brain, Bone, Ovary, Pituitary, Cervix, Myeloid

Publications for Peripheral Nervous System Neoplasm

Articles related to Peripheral Nervous System Neoplasm:

# Title Authors Year
1
Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms. ( 29762158 )
2018

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

Pathways related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 AKT1 ALK CASP3 NGF NTRK1 NTRK2
2
Show member pathways
12.95 AKT1 CASP3 MYC NGF NTRK1 NTRK2
3 12.82 AKT1 ALK CASP3 MYC NTRK1 TP53
4
Show member pathways
12.81 AKT1 CASP3 MYC NTRK1 TP53
5
Show member pathways
12.78 AKT1 CASP3 MYC NGF NTRK1 TP53
6
Show member pathways
12.7 AKT1 NF1 NGF NTRK1 NTRK2
7
Show member pathways
12.68 AKT1 CASP3 NGF NTRK1 NTRK2 TP53
8
Show member pathways
12.43 AKT1 CASP3 MYC TH
9 12.43 AKT1 CASP3 MYC NF1 NGF NTRK1
10
Show member pathways
12.41 AKT1 CASP3 NTRK1 NTRK2 TP53
11 12.26 AKT1 CASP3 MYC TP53
12 12.25 AKT1 CASP3 MYC TP53
13
Show member pathways
12.22 AKT1 MYC NGF NTRK1 NTRK2 TP53
14 12.21 MYC MYCN NTRK1 TP53
15 12.16 AKT1 CASP3 MYC TP53
16 12.13 CASP3 NGF NTRK2 PHOX2B TH
17 12.1 AKT1 CASP3 MYC NF1 TP53
18 12.01 AKT1 CASP3 NGF NTRK1 NTRK2
19 12 AKT1 CASP3 MYC NTRK1 NTRK2 TP53
20 11.94 AKT1 MYC NF1 TP53
21
Show member pathways
11.92 AKT1 CASP3 MYC NGF NTRK1 TP53
22 11.85 AKT1 CASP3 MYC TP53
23 11.76 BACE1 ENO2 MYCN NF1 NGF NTRK1
24 11.7 AKT1 CASP3 TP53
25
Show member pathways
11.68 AKT1 CASP3 NGF TP53
26
Show member pathways
11.68 AKT1 CASP3 MFRP MYC NTRK1 NTRK2
27 11.66 AKT1 MYC NTRK1 TP53
28
Show member pathways
11.61 NGF NTRK1 NTRK2
29 11.54 AKT1 CNTN6 MYC MYCN TP53
30 11.53 AKT1 BACE1 CASP3 TP53
31 11.46 BACE1 NTRK1 NTRK2
32 11.45 NGF NTRK1 NTRK2
33 11.44 AKT1 CASP3 MYC TP53
34 11.37 AKT1 CASP3 MYC TP53
35 11.29 AKT1 CASP3 NGF
36 10.82 CASP3 NTRK2
37
Show member pathways
10.69 NGF NTRK1 NTRK2
38 10.33 MYC MYCN

GO Terms for Peripheral Nervous System Neoplasm

Cellular components related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.55 BACE1 CASP3 ENO2 NTRK1 TH
2 dendrite GO:0030425 9.43 BACE1 NF1 NGF NTRK1 NTRK2 TH
3 axon GO:0030424 9.17 BACE1 CNTN6 NF1 NGF NTRK1 NTRK2

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 AKT1 ALK CD34 MYC TP53
2 negative regulation of gene expression GO:0010629 9.96 AKT1 CD34 MYC MYCN
3 positive regulation of apoptotic process GO:0043065 9.93 AKT1 CASP3 NF1 NGF TP53
4 positive regulation of protein phosphorylation GO:0001934 9.88 AKT1 ALK NTRK1 NTRK2
5 nervous system development GO:0007399 9.88 AKT1 ALK CNTN6 NTRK1 NTRK2 NUMBL
6 protein autophosphorylation GO:0046777 9.87 AKT1 ALK NTRK1 NTRK2
7 cytokine-mediated signaling pathway GO:0019221 9.85 AKT1 CASP3 MYC NUMBL TP53
8 cerebral cortex development GO:0021987 9.81 NF1 NTRK2 TH
9 neuron differentiation GO:0030182 9.81 CASP3 CNTN6 NTRK2 PHOX2B
10 cellular response to organic cyclic compound GO:0071407 9.8 AKT1 CASP3 MYC
11 cellular response to drug GO:0035690 9.79 MYC TH TP53
12 cellular response to growth factor stimulus GO:0071363 9.77 AKT1 NTRK1 TH
13 negative regulation of neuron death GO:1901215 9.77 AKT1 CD34 NTRK1
14 positive regulation of neuron apoptotic process GO:0043525 9.73 BACE1 CASP3 NF1
15 response to nicotine GO:0035094 9.7 CASP3 NTRK1 TH
16 positive regulation of gene expression GO:0010628 9.7 AKT1 CD34 MYC MYCN NGF NTRK2
17 cellular response to nerve growth factor stimulus GO:1990090 9.67 AKT1 NTRK1 NTRK2
18 detection of mechanical stimulus involved in sensory perception of pain GO:0050966 9.65 BACE1 NTRK1
19 nerve growth factor signaling pathway GO:0038180 9.65 NGF NTRK1
20 positive regulation of mitochondrial membrane potential GO:0010918 9.64 AKT1 MYC
21 cellular response to manganese ion GO:0071287 9.63 BACE1 TH
22 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 MYCN TP53
23 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.62 ALK NGF NTRK1 NTRK2
24 cellular response to nicotine GO:0071316 9.61 NTRK1 TH
25 negative regulation of fibroblast proliferation GO:0048147 9.61 MYC NF1 TP53
26 negative regulation of apoptotic process GO:0043066 9.56 AKT1 ALK CASP3 MYC NGF NTRK1
27 mechanoreceptor differentiation GO:0042490 9.55 NTRK1 NTRK2
28 response to gamma radiation GO:0010332 9.54 MYC TP53 TRIM13
29 neurotrophin signaling pathway GO:0038179 9.48 NTRK1 NTRK2
30 sympathetic nervous system development GO:0048485 9.43 NF1 NTRK1 PHOX2B
31 neurotrophin TRK receptor signaling pathway GO:0048011 8.92 CASP3 NGF NTRK1 NTRK2
32 negative regulation of cell proliferation GO:0008285 10 NF1 NGF NTRK1 PHOX2B TP53

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 ALK NTRK1 NTRK2
2 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK2
3 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK2

Sources for Peripheral Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....